<DOC>
	<DOCNO>NCT02643420</DOCNO>
	<brief_summary>The purpose study compare efficacy single dose SPI-2012 pegfilgrastim ( Neulasta [ NDC 55513-190-01 ] manufacture Amgen ) patient early-stage breast cancer receive docetaxel cyclophosphamide ( TC ) , measure Duration Severe Neutropenia ( DSN ) Cycle 1 .</brief_summary>
	<brief_title>RAnDomized Trial SPI-2012 Versus Pegfilgrastim Management Chemotherapy Induced Neutropenia Breast CANCEr Patients Receiving Docetaxel Cyclophosphamide</brief_title>
	<detailed_description>This Phase 3 , randomize , open-label , active-controlled , multicenter study compare efficacy safety SPI-2012 ( long act myeloid growth factor ) pegfilgrastim ( Neulasta [ NDC 55513-190-01 ] manufacture Amgen ) breast cancer patient treat TC chemotherapy . Approximately 580 patient enrol randomized 1:1 ratio 2 treatment arm . Each cycle 21 day . Only 4 cycle evaluate study . On Day 1 cycle , patient receive TC chemotherapy . On Day 2 cycle , patient receive study drug ( SPI-2012 pegfilgrastim ) . After Cycle 1 , patient receive least one dose study drug follow 12 month last dose study treatment safety follow-up .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Key New diagnosis histologically confirm earlystage breast cancer ( ESBC ) , define operable Stage I Stage IIIA breast cancer . Candidate receive adjuvant neoadjuvant TC chemotherapy . ECOG ≤2 . ANC ≥1.5×10^9/L Platelet count ≥100×10^9/L Hemoglobin &gt; 9 g/dL Calculated creatinine clearance &gt; 50 mL/min Total bilirubin ≤1.5 mg/dL AST/SGOT ALT/SGPT ≤2.5×ULN Alkaline phosphatase ≤1.5×ULN Key Active concurrent malignancy ( except non melanoma skin cancer carcinoma situ cervix ) lifethreatening disease . Known sensitivity E. coli derive product know sensitivity product administer dose Concurrent adjuvant cancer therapy Locally recurrent/metastatic contralateral breast cancer . Previous exposure filgrastim , pegfilgrastim , GCSF product clinical development prior administration study drug Active infection serious underlie medical condition , would impair ability patient receive protocol treatment Prior bone marrow stem cell transplant Used investigational drug , biologics , device within 30 day prior study treatment plan use course study . Prior radiation therapy within 30 day prior enrollment . Major surgery within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Long-acting Myeloid Growth Factor</keyword>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>Docetaxel + Cyclophosphamide ( TC ) chemotherapy</keyword>
</DOC>